^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Ependymoma

Related cancers:
Phase 2
Children's Hospital Medical Center, Cincinnati
Suspended
Last update posted :
06/12/2024
Initiation :
05/08/2017
Primary completion :
06/01/2024
Completion :
06/01/2025
NF2
|
NF2 mutation
|
Koselugo (selumetinib)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/10/2024
Initiation :
05/22/2015
Primary completion :
12/31/2026
Completion :
12/31/2026
PD-L1 • TMB
|
TMB-H
|
Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
Phase N/A
National Cancer Institute (NCI)
Completed
Last update posted :
06/10/2024
Initiation :
12/05/2006
VEGFA • TNFA
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/06/2024
Initiation :
07/31/2017
Primary completion :
09/30/2027
Completion :
09/30/2027
BRAF
|
Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
07/13/2017
Primary completion :
04/21/2026
Completion :
04/21/2027
BCOR • FOXR2
|
Opdivo (nivolumab)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
01/31/2024
Primary completion :
11/14/2028
Completion :
11/14/2033
MYCN
|
MYCN amplification
|
PLX038
Phase 1
Sabine Mueller, MD, PhD
Recruiting
Last update posted :
06/04/2024
Initiation :
05/31/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
TGFB1 • TGFBI
Phase 1
St. Jude Children's Research Hospital
Completed
Last update posted :
05/31/2024
Initiation :
03/05/2018
Primary completion :
09/30/2022
Completion :
05/24/2024
PTCH1
|
PTCH1 mutation
|
Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/21/2024
Initiation :
08/13/2018
Primary completion :
03/31/2023
Completion :
09/22/2024
RB1
|
Ibrance (palbociclib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/21/2024
Initiation :
11/28/2017
Primary completion :
09/30/2023
Completion :
10/01/2024
PTEN • TSC2 • TSC1
|
PTEN expression • TSC1 mutation • TSC2 mutation
|
samotolisib (LY3023414)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/21/2024
Initiation :
08/23/2017
Primary completion :
09/30/2024
Completion :
09/30/2024
NTRK
|
NTRK fusion
|
Vitrakvi (larotrectinib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/17/2024
Initiation :
11/08/2017
Primary completion :
06/30/2022
Completion :
09/22/2024
BRAF
|
BRAF mutation • BRAF V600
|
Zelboraf (vemurafenib)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/29/2024
Initiation :
03/13/2014
Primary completion :
10/19/2021
Completion :
10/19/2024
EGFR
|
EGFR amplification
|
lapatinib
Phase 1
Pediatric Brain Tumor Consortium
Active, not recruiting
Last update posted :
04/08/2024
Initiation :
03/01/2018
Primary completion :
09/30/2023
Completion :
09/30/2024
TMB • CD4
|
sotigalimab (PYX-107)
Phase 1
Istari Oncology, Inc.
Completed
Last update posted :
04/08/2024
Initiation :
11/07/2017
Primary completion :
03/23/2022
Completion :
03/23/2022
NF1
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
Phase N/A
Giselle Sholler
Completed
Last update posted :
04/05/2024
Initiation :
07/08/2014
Primary completion :
01/18/2024
Completion :
01/18/2024
MYCN
|
MYCN amplification
Phase 1
Pediatric Brain Tumor Consortium
Recruiting
Last update posted :
04/05/2024
Initiation :
07/27/2022
Primary completion :
07/20/2028
Completion :
07/20/2043
HER-2
|
HER-2 positive
|
cyclophosphamide
Phase 1
Wake Forest University Health Sciences
Recruiting
Last update posted :
04/03/2024
Initiation :
03/13/2019
Primary completion :
07/01/2024
Completion :
09/01/2024
KDR • CD24 • POU5F1 • VEGFC
Phase 2
Pediatric Brain Tumor Consortium
Active, not recruiting
Last update posted :
03/29/2024
Initiation :
04/04/2022
Primary completion :
10/30/2029
Completion :
10/30/2030
CD276
|
Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
Phase 1
University of Colorado, Denver
Completed
Last update posted :
03/15/2024
Initiation :
06/25/2013
Primary completion :
09/21/2021
Completion :
07/21/2023
AIF1
Phase 1
St. Jude Children's Research Hospital
Recruiting
Last update posted :
03/13/2024
Initiation :
04/27/2023
Primary completion :
03/01/2028
Completion :
03/01/2028
CD276
|
B7-H3 CAR-T
Phase 2
Scott R. Plotkin, MD, PhD
Recruiting
Last update posted :
03/13/2024
Initiation :
06/20/2020
Primary completion :
12/01/2029
Completion :
12/01/2030
NF2
|
Nerlynx (neratinib) • Alunbrig (brigatinib)
Phase 2
Monica Thakar
Completed
Last update posted :
03/12/2024
Initiation :
03/20/2013
Primary completion :
06/08/2020
Completion :
07/15/2020
HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
Phase 1/2
University Hospital Heidelberg
Recruiting
Last update posted :
02/07/2024
Initiation :
05/26/2020
Primary completion :
06/30/2026
Completion :
06/30/2027
PD-L1 • TMB • MYC
|
PD-L1 expression
|
Opdivo (nivolumab) • Jingzhuda (entinostat)
Phase 1
Washington University School of Medicine
Completed
Last update posted :
01/31/2024
Initiation :
10/26/2012
Primary completion :
12/27/2023
Completion :
12/27/2023
CD34
|
cyclophosphamide • thalidomide • cyclophosphamide intravenous
Phase 1
University of Colorado, Denver
Recruiting
Last update posted :
12/25/2023
Initiation :
12/01/2016
Primary completion :
11/01/2025
Completion :
03/01/2026
CSF2
|
Herceptin (trastuzumab)
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
12/20/2023
Initiation :
07/26/2018
Primary completion :
07/26/2024
Completion :
07/26/2039
HER-2
|
HER-2 positive
|
HER2-Specific CAR T
Phase 1
Seattle Children's Hospital
Recruiting
Last update posted :
12/20/2023
Initiation :
12/11/2019
Primary completion :
05/01/2026
Completion :
05/01/2041
CD276
|
CD276 expression
|
SCRI-CARB7H3(s)
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
10/27/2023
Initiation :
03/19/2019
Primary completion :
03/01/2025
Completion :
03/01/2040
EGFR
|
EGFR expression • EGFR positive
|
EGFR806-specific CAR T-cell therapy
Phase 1
M.D. Anderson Cancer Center
Withdrawn
Last update posted :
10/04/2023
Initiation :
01/14/2021
Primary completion :
12/20/2022
Completion :
12/20/2022
HLA-DRB1 • HLA-B • HLA-C • KIR2DS2
|
etoposide IV • melphalan • fludarabine IV • thiotepa
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/08/2023
Initiation :
07/18/2017
Primary completion :
12/01/2024
Completion :
12/01/2025
IDH1
|
IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132
|
cyclophosphamide • CAN-3110
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/07/2023
Initiation :
07/13/2017
Primary completion :
07/01/2024
Completion :
07/01/2024
EGFR • FGFR
|
IDH wild-type
|
cisplatin • Verzenio (abemaciclib)
Phase 2
Radiation Therapy Oncology Group
Completed
Last update posted :
06/14/2022
Initiation :
01/01/2005
Primary completion :
02/01/2013
Completion :
05/20/2022
MGMT
|
temozolomide
Phase 1
Pediatric Brain Tumor Consortium
Completed
Last update posted :
08/27/2021
Initiation :
01/13/2018
Primary completion :
04/01/2020
Completion :
04/01/2020
RB1
|
everolimus • Kisqali (ribociclib)
Phase 2
Northwestern University
Completed
Last update posted :
01/22/2021
Initiation :
06/17/2010
Primary completion :
03/10/2014
Completion :
12/31/2018
HER-2
|
HER-2 expression • VEGFA expression
|
Avastin (bevacizumab)
Phase 1
Emory University
Completed
Last update posted :
05/29/2020
Initiation :
04/01/2011
Primary completion :
08/09/2017
Completion :
08/09/2017
AFP
|
sirolimus
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
12/09/2019
Initiation :
09/22/2009
Completion :
03/19/2013
AFP
|
temozolomide • veliparib (ABT-888)
Phase 1/2
Northwestern University
Completed
Last update posted :
09/26/2019
Initiation :
08/01/2011
Primary completion :
06/20/2016
Completion :
01/20/2019
HER-2
|
HER-2 positive
|
Herceptin (trastuzumab)